Sector News

Bristol-Myers expands I/O hub

April 15, 2016
Life sciences

Bristol-Myers Squibb is once again growing its footprint in the fast-growing immuno-oncology R&D world.

The biopharma company inked a lease on the third and final facility BioMed Realty owns at Woodside Technology Park in Redwood City, CA, opening the door to an expansion of its biologics discovery team, set to grow from the 250 now employed at the hub to as many as 400 with the add-on.

Bristol-Myers’ deal nabbed the last 62,000 square feet of space at the park, which brings its total in the Bay Area Peninsula biotech area to 256,000 square feet–a clean sweep of the campus it first moved into close to three years ago. A spokesperson for the company tells FierceBiotech that the expansion could add up to 150 staffers on site.

The campus is devoted primarily to the company’s big R&D efforts in immuno-oncology, a field that Bristol-Myers now dominates with its pioneering drug Opdivo.

The leases for Bristol-Myers started back in 2013, when the company inked a contract for the first big building on the site. The second facility was taken in 2014.

During the past three years Bristol-Myers has been steadily upping its game in I/O. Opdivo–a pioneering drug designed to unleash an immune system assault on cancer cells–has been quickly penetrating the vast oncology market, nabbing label expansions and competing head-to-head with Merck’s Keytruda.

“The expansion of our facilities in Redwood City is evidence of the value that Bristol-Myers Squibb sees in the Bay Area scientific community and our relationship with BioMed Realty,” said Nils Lonberg, head of oncology biology discovery at Bristol-Myers Squibb.

By John Carroll

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).